Dabrafenib,Trametinib
Novartis
['trametinib', 'roar', 'dabrafenib']
first win for #precisionmedicine in rare cancer patients from the roar trial 3/10 dabrafenib and trametinib treatment in patients with locally advanced or metastatic braf v600 mutant anaplastic thyroid cancer lead to fda approval in this deadly cancer #aacr23 
Oncologist | Associate Prof | Executive Director-Research, MD Anderson Cancer Network | Medical Director, Clinical Center for Targeted Therapy. Tweets = my own.